Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours

Oncogene volume 20, pages 4416–4418 (2001)Cite this article

Abstract

Mutations in FGFR3 have been identified in several tumour types including bladder carcinoma, cervical carcinoma, and multiple myeloma. In bladder carcinoma, we recently identified FGFR3 mutations in 41% of tumours, making this the most frequently mutated putative oncogene identified in bladder cancer to date. We have now investigated the frequency of FGFR3 mutation in a panel of 125 tumours and 13 cell lines from various other organs. We analysed the mutation hotspots in exons 7, 10 and 15 by direct DNA sequencing, and found one mutation in exon 7 (S249C) in 1/28 (3.5%) cervical tumours. Mutations were not detected in stomach, rectum, colon, prostate, ovarian, breast, brain, or renal tumours, nor were they found in any of the cell lines included in this study. We conclude that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical carcinoma. Several tumour types appear not to possess any mutations in FGFR3, suggesting that these mutations are important only in the development of certain types of tumour.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Bloom ET . 1972 Cancer Res. 32: 960–967

  • Brady CS, Duggan-Keen MF, Davidson JA, Varley JM, Stern PL . 1999 J. Gen. Virol. 80: 3233–3240

  • Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F . 1999 Nat. Genet. 23: 18–20

  • Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL . 1997 Nat. Genet. 16: 260–264

  • Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL . 1998 Blood 92: 3025–3034

  • Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP . 1983 Cancer Res. 43: 1809–1818

  • Jones PA, Rhim JS, Isaacs Jr H, McAllister RM . 1975 Int. J. Cancer 16: 616–621

  • Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW . 1979 Invest. Urol. 17: 16–23

  • Lozzio CB, Lozzio BB . 1975 Blood 45: 321–334

  • Passos-Bueno MR, Wilcox WR, Jabs EW, Sertie AL, Alonso LG, Kitoh H . 1999 Hum. Mutat. 14: 115–125

  • Proctor AJ, Coombs LM, Cairns JP, Knowles MA . 1991 Oncogene 6: 789–795

  • Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, Rocchi M, Otsuki T, Lombardi L, Maiolo AT, Neri A . 1997 Blood 90: 4062–4070

  • Stein GH . 1979 J. Cell. Physiol. 99: 43–54

  • Sibley K, Cuthbert-Heavens D, Knowles MA . 2001 Oncogene 20: 686–691

  • Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF . 1978 Int. J. Cancer 21: 274–281

  • Taylor-Papadimitriou J, Purkis P, Lane EB, McKay IA, Chang SE . 1982 Cell Differ. 11: 169–180

  • Tumilowicz JJ, Nichols WW, Cholon JJ, Greene AE . 1970 Cancer Res. 30: 2110–2118

  • Webster MK, Donoghue DJ . 1996 EMBO J. 15: 520–527

  • Webster MK, Donoghue DJ . 1997 Mol. Cell. Biol. 17: 5739–5747

  • Wu R, Connolly D, Ngelangel C, Bosch FX, Munoz N, Cho KR . 2000 Oncogene 19: 5543–5546

  • Wuchner C, Hilbert K, Zabel B, Winterpacht A . 1997 Hum. Genet. 100: 215–219

  • Yee CJ, Lin O, Boyd J . 2000 J. Natl. Cancer Inst. 92: 1848–1849

Download references

Acknowledgements

We thank the following for the generous gift of tumour DNA samples: Dr Hiroyuki Nishiyama for renal cell carcinomas and Dr Pat Harnden for brain tumours. We also thank Dr Sue Burchill for DNA from the Ewing's sarcoma and neuroblastoma cell lines and Claire Brady for preparing DNA from cervical tumours. This work was supported by The Imperial Cancer Research Fund (K Sibley, MA Knowles) and the Cancer Research Campaign (P Stern).

Author information

Authors and Affiliations

  1. ICRF Clinical Centre, St. James's University Hospital, Leeds, LS9 7TF, UK

    Kathryn Sibley & Margaret A Knowles

  2. CRC Immunology Group, Paterson Institute for Cancer Research, Manchester, M20 4BX, UK

    Peter Stern

Authors
  1. Kathryn Sibley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Stern
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Margaret A Knowles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret A Knowles.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sibley, K., Stern, P. & Knowles, M. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 20, 4416–4418 (2001). https://doi.org/10.1038/sj.onc.1204543

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204543

Keywords

This article is cited by

Search

Advanced search

Quick links